The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.35
Bid: 2.30
Ask: 2.40
Change: -0.05 (-2.08%)
Spread: 0.10 (4.348%)
Open: 2.45
High: 2.50
Low: 2.35
Prev. Close: 2.40
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 May 2018 17:26

RNS Number : 0951N
Shield Therapeutics PLC
03 May 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Shield Therapeutics PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

SPREADEX LTD

City and country of registered office (if applicable)

St Albans, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

01/05/2018

6. Date on which issuer notified (DD/MM/YYYY):

03/05/2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

2.79%

0.75%

3.54%

116,425,851

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYV81293

3,250,000

2.79%

SUBTOTAL 8. A

3,250,000

2.79%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

CFD/SPREADBET

867,500

0.75%

SUBTOTAL 8. B 1

867,500

0.75%

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

David Corben

01727895135

 

Place of completion

UK

Date of completion

03/05/2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLAJMFTMBTMBJP
Date   Source Headline
6th Apr 202111:00 amRNSPrice Monitoring Extension
6th Apr 20217:00 amRNSHolding(s) in Company
31st Mar 20213:01 pmRNSTotal Voting Rights Update
31st Mar 20213:00 pmRNSBlock Listing 6 Monthly Return
30th Mar 20217:00 amRNSInvestor presentation
26th Mar 20217:00 amRNSStudy demonstrates effectiveness of ferric maltol
24th Mar 20215:40 pmRNSBlock Listing Application
23rd Mar 20215:53 pmRNSHolding(s) in Company
23rd Mar 202112:23 pmRNSHolding(s) in Company
22nd Mar 20217:00 amRNSShield appoints new Chief Financial Officer
18th Mar 20212:02 pmRNSResult of General Meeting & Open Offer
15th Mar 20215:21 pmRNSHolding(s) in Company
9th Mar 20217:00 amRNSAustralia's TGA approves Feraccru
5th Mar 20214:54 pmRNSPDMR Transaction Notification
4th Mar 20216:17 pmRNSPDMR/PCA Transaction Notification
3rd Mar 20211:40 pmRNSInvestor Presentation
1st Mar 20217:00 amRNSPublication of Circular and Notice of GM
26th Feb 20214:09 pmRNSSuccessful completion of £25 million Fundraise
26th Feb 202112:30 pmRNSTotal Voting Rights Update
26th Feb 202111:05 amRNSSecond Price Monitoring Extn
26th Feb 202111:00 amRNSPrice Monitoring Extension
26th Feb 20219:30 amRNSPlacing and Subscription to raise up to £25m
19th Feb 202111:05 amRNSSecond Price Monitoring Extn
19th Feb 202111:00 amRNSPrice Monitoring Extension
2nd Feb 20218:00 amEQSEdison Investment Research Limited: Shield Therapeutics (STX): Beefing up for the US opportunity
29th Jan 20212:38 pmRNSShareholder loan facilities
29th Jan 20217:00 amRNSTotal Voting Rights Update
21st Jan 20215:41 pmRNSDirector/PDMR Shareholding
19th Jan 20212:20 pmRNSDirector/PDMR Shareholding
15th Jan 202110:00 amRNSInvestor presentation
15th Jan 20217:00 amRNSBusiness and trading update
14th Jan 202111:05 amRNSSecond Price Monitoring Extn
14th Jan 202111:00 amRNSPrice Monitoring Extension
6th Jan 20217:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Reassessing the US opportunity
31st Dec 20207:00 amRNSTotal Voting Rights Update
22nd Dec 202010:06 amRNSHolding(s) in Company
21st Dec 20207:00 amRNSInvestor Presentation
18th Dec 20205:21 pmRNSGrant of share options to the CEO
18th Dec 20205:15 pmRNSPDMR Exercise of Share Options
14th Dec 20207:00 amRNSDirector/PDMR Shareholding
14th Dec 20207:00 amRNSInvestor Presentation
10th Dec 202011:05 amRNSSecond Price Monitoring Extn
10th Dec 202011:00 amRNSPrice Monitoring Extension
10th Dec 20207:00 amRNSUpdate re US partnering discussions
30th Nov 20207:00 amRNSHolding(s) in Company
30th Nov 20207:00 amRNSTotal Voting Rights Update
2nd Nov 20207:00 amRNSTotal Voting Rights Update
19th Oct 20207:00 amRNSWithdrawal of all oppositions by TEVA
30th Sep 20201:21 pmRNSBlock Listing 6 Monthly Return
30th Sep 20201:20 pmRNSTotal Voting Rights Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.